Please assess the completion status of the following clinical trial:

Trial Title: SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer~* Candidate for adjuvant or neo-adjuvant TC chemotherapy~* Eastern Cooperative Oncology Group (ECOG) performance status \<= 2~* Absolute neutrophil count (ANC) \>=1.5×10\^9/L~* Platelet count \>=100×10\^9/L~* Hemoglobin \>9 g/dL~* Calculated creatinine clearance \> 50 mL/min~* Total bilirubin \<=1.5 mg/dL~* Aspartate aminotransferase (AST) / Serum glutamic oxaloacetic transaminase (SGOT) and Alanine aminotransferase (ALT)/Serum glutamic pyruvic transaminase (SGPT) \<=2.5×ULN (upper limit of normal)~* Alkaline phosphatase \<=2.0×ULN~Key Exclusion Criteria:~* Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of the cervix) or life-threatening disease~* Locally recurrent/metastatic breast cancer~* Known sensitivity to E. coli-derived products~* Concurrent adjuvant cancer therapy~* Previous exposure to filgrastim, pegfilgrastim, or other G-CSF products in clinical development within 12 months prior to the administration of study drug~* Active infection, receiving anti-infectives, or any underlying medical condition that would impair ability to receive protocol treatment~* Prior bone marrow or stem cell transplant~* Used any investigational drugs, biologics, or devices within 30 days prior to study treatment or plans to use any of these during the course of the study• Radiation therapy within 30 days prior to enrollment~* Major surgery within 30 days prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- (Arm 1): SPI-2012 and TC (Type: EXPERIMENTAL): At each cycle for 4 cycles, participants received SPI-2012 at a fixed dose of 13.2 milligrams (mg)/0.6 milliliter (mL), \[3.6 mg granulocyte colony-stimulating factor {G-CSF}\] subcutaneously (SC) approximately 24-26 hours after receiving intravenous (IV) infusion of docetaxel 75 mg/m\^2 and cyclophosphamide 600 mg/m\^2 IV infusion per institute's standard of care. All participants were followed for 35 (±5) days after last study treatment or patient discontinuation and long-term safety follow-up continued for 12 months after last dose of study treatment.
- (Arm 2): Pegfilgrastim and TC (Type: EXPERIMENTAL): At each cycle for 4 cycles, participants received pegfilgrastim 6 mg (6 mg/0.6 mL GCSF) SC approximately 24-26 hours after receiving IV infusion of docetaxel 75 mg/m\^2 and cyclophosphamide 600 mg/m\^2 IV infusion per institute's standard of care. All participants were followed for 35 (±5) days after last study treatment or patient discontinuation and long-term safety follow-up continued for 12 months after last dose of study treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).